John Newman
Stock Analyst at Canaccord Genuity
(2.19)
# 2,888
Out of 5,090 analysts
88
Total ratings
45.45%
Success rate
-4.62%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $850 → $1,057 | $717.99 | +47.22% | 20 | Dec 4, 2025 | |
| CMPX Compass Therapeutics | Initiates: Buy | $10 | $5.51 | +81.49% | 1 | Dec 3, 2025 | |
| NUVL Nuvalent | Initiates: Buy | $126 | $109.64 | +14.92% | 1 | Nov 12, 2025 | |
| ACLX Arcellx | Maintains: Buy | $121 → $130 | $68.96 | +88.52% | 9 | Nov 3, 2025 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $9.79 | +114.50% | 2 | Oct 21, 2025 | |
| MRUS Merus | Downgrades: Hold | $67 → $97 | $96.17 | +0.86% | 3 | Sep 30, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $14 → $22 | $16.60 | +32.53% | 10 | Sep 24, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.43 | +879.02% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $96.23 | +78.16% | 8 | Mar 11, 2025 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 | $14.52 | +17.08% | 5 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.34 | +499.25% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $25 | $5.29 | +372.59% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $8 | $0.54 | +1,391.70% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $6.95 | +518.71% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.00 | +400.85% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $27.86 | +57.93% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $14.18 | +168.05% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $4.68 | +476.92% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $15.60 | - | 1 | Sep 13, 2017 |
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Buy
Price Target: $850 → $1,057
Current: $717.99
Upside: +47.22%
Compass Therapeutics
Dec 3, 2025
Initiates: Buy
Price Target: $10
Current: $5.51
Upside: +81.49%
Nuvalent
Nov 12, 2025
Initiates: Buy
Price Target: $126
Current: $109.64
Upside: +14.92%
Arcellx
Nov 3, 2025
Maintains: Buy
Price Target: $121 → $130
Current: $68.96
Upside: +88.52%
Delcath Systems
Oct 21, 2025
Maintains: Buy
Price Target: $21
Current: $9.79
Upside: +114.50%
Merus
Sep 30, 2025
Downgrades: Hold
Price Target: $67 → $97
Current: $96.17
Upside: +0.86%
Seres Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $14 → $22
Current: $16.60
Upside: +32.53%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.43
Upside: +879.02%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $96.23
Upside: +78.16%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $14.52
Upside: +17.08%
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.34
Upside: +499.25%
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $5.29
Upside: +372.59%
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.54
Upside: +1,391.70%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $6.95
Upside: +518.71%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $1.00
Upside: +400.85%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $27.86
Upside: +57.93%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $14.18
Upside: +168.05%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $4.68
Upside: +476.92%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $15.60
Upside: -